Virus Sampling News
-
Viral Vector Manufacturing
In recent years, applications of viral vectors have found an encouraging new beginning in gene therapy and in vaccine development. What can viral vectors be used for? Substantial improvements in viral vector manufacturing, delivery, and safety have placed viral vector-based therapy at the forefront of modern medicine. Viral vectors can be used for the treatment of various ...
By Nuvonis
-
Virica Biotech to be Showcased in Xtalks Webinar: Process Intensification in AAV Gene Therapy
Virica Biotech Inc. (“Virica”), a leading developer of solutions for scaling of viral medicines, will be featured in a live webinar to be held on Monday, November 14, 2022, at 2:30pm EST. This webinar will focus on process intensification in the manufacturing of adeno associated virus (AAV) vectors. AAV vectors are critical to gene therapy development. These vectors are the delivery ...
-
BiomX Announces Publication in the Journal, Bioinformatics
BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the publication of a scientific paper titled “Exodus: Sequencing-based Pipeline for Quantification of Pooled Variants” in the journal, Bioinformatics. ...
By BiomX
-
ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases
ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases The companies agree a follow-on collaboration to evaluate ViGeneron’s adeno-associated virus vectors (vgAAVs) for delivering Daiichi Sankyo’s novel therapeutic protein to treat prevalent eye diseases ViGeneron GmbH, a next-generation gene therapy company, ...
-
ViGeneron signs gene therapy strategic collaboration and option agreement with Regeneron for one inherited retinal disease target
Regeneron receives access to ViGeneron’s vgAAV capsids for one inherited retinal disease target and an option for an exclusive license to develop and commercialize the gene therapy product ViGeneron is eligible to receive upfront payment, research funding, option exercise fee, development and commercial milestone payments, plus royalties on net sales The collaboration further validates ...
-
Quidel’s Antigen Tests Detect the Omicron Variant
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, issued the following statement from Douglas Bryant, Quidel’s President and CEO, regarding Quidel’s ongoing efforts to evaluate COVID-19 mutations and confirm that its antigen tests continue to detect COVID-19 ...
-
Equine Today: The Importance of Having a Biosecurity Program at your Practice
Fluxergy’s is launching its environmental salmonella assay where equine practices and facilities can add in-house PCR testing to their biosecurity program. This avoids central lab processing and allows clinicians to clear stalls after simple overnight enrichment. Contact Sales What is Biosecurity? Biosecurity describes all the human actions that go into preventing disease in horses and ...
By Fluxergy
-
Delivering gene therapy’s promise
The human body consists of trillions of cells, each possessing their own copy of DNA that provides the blueprint for making a human. Despite sharing the same DNA, different cells activate a varied mix of genes within them to enable differentiation into various tissues and organs. For millions of people, unfortunately, some of these genes do not function properly, resulting in diseases and ...
-
ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ophthalmic gene therapy
ViGeneron GmbH, a gene therapy company, today announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV) vectors with Daiichi Sankyo Company, Limited (“Daiichi Sankyo”), for delivering a novel therapeutic protein to address an undisclosed target in a highly prevalent ophthalmic disease. ViGeneron’s vgAAVs enable the efficient transduction ...
-
ViGeneron signs global collaboration agreement for ophthalmic gene therapy development
Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional target The companies will use ViGeneron’s proprietary vgAAV technology to efficiently transduce target cells via intravitreal injections ViGeneron GmbH, a gene therapy company, today announced a global collaboration and licensing agreement with Biogen ...
-
T-knife and Catalent Sign Technology Transfer and Manufacturing Agreement for Autologous T-Cell Receptor-Based Cell Therapy
BERLIN, GERMANY, and SOMERSET, N.J. – September 21, 2020 — T-knife GmbH, a next-generation adoptive T-cell company using its proprietary humanized T-cell receptor (HuTCR) mouse platform to treat solid tumors, and Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, ...
By T-Knife GmbH
-
QuarkBio Announced its COVID-19 Test Kit 10 Times More Sensitive than Existing Kit
Quark Biosciences Inc. announced today the successful development of a novel digital PCR test, DigiChip SARS-CoV-2 Assay, that is 10x more sensitive than conventional diagnostic methods. The company plans to work with Shin Kong Memorial Hospital and a California-based medical group for clinical validation and to apply for regularly approval. The assay is capable of detecting ...
-
Patent protection for innovative technology-platform
BlueSky Immunotherapies has expanded and secured its intellectual property portfolio. The patents based on WO2015/063085 cover a recombinant influenza virus vector comprising an NS gene encoding a truncated NS1 protein and forms the basis of the company’s technology platform. Corresponding patents were recently granted in (EP 3063273), USA (US 10480013), and China (CN 2019112100112140) ...
-
Scientists Develop New Vaccine to Protect Against Two Important Diseases
USPOULTRY and the USPOULTRY Foundation announce the completion of a funded research project at North Carolina State University in Raleigh, N.C., that evaluated a new vaccine to protect again two important diseases. The project is part of the Association’s comprehensive research program encompassing all phases of poultry and egg production and processing. A brief summary of the completed ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you